Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Crinetics Pharmaceuticals Inc (CRNX)

Crinetics Pharmaceuticals Inc (CRNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences GlobeNewswire - Fri Nov 15, 8:00AM CST

CRNX : 57.03 (+1.71%)
Crinetics Pharmaceuticals to Showcase Novel Nonpeptide Drug Conjugate Platform and Phase 2 Data for Paltusotine at NANETS 2024 Quiver Quantitative, Inc. - Fri Nov 15, 1:20AM CST

Crinetics Pharmaceuticals will present preclinical data on CRN09682 and Paltusotine at NANETS 2024.Quiver AI SummaryCrinetics Pharmaceuticals, Inc. announced the debut of its innovative nonpeptide drug...

CRNX : 57.03 (+1.71%)
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting GlobeNewswire - Thu Nov 14, 3:05PM CST

CRNX : 57.03 (+1.71%)
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting GlobeNewswire - Tue Nov 12, 3:07PM CST

CRNX : 57.03 (+1.71%)
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update GlobeNewswire - Tue Nov 12, 3:05PM CST

CRNX : 57.03 (+1.71%)
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon Nov 11, 3:05PM CST

CRNX : 57.03 (+1.71%)
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024 GlobeNewswire - Wed Oct 16, 7:00AM CDT

CRNX : 57.03 (+1.71%)
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Thu Oct 10, 3:40PM CDT

CRNX : 57.03 (+1.71%)
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock GlobeNewswire - Tue Oct 8, 10:55PM CDT

CRNX : 57.03 (+1.71%)
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire - Tue Oct 8, 3:01PM CDT

CRNX : 57.03 (+1.71%)

Barchart Exclusives

1 AI Stock to Buy and Hold for Long-Term Growth Barchart - Thu Nov 21, 7:18PM CST
Pure Storage stands out in AI data storage, bolstered by a new partnership with CoreWeave and a solid financial track record, making it an intriguing stock for AI-focused investors Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot